DEF 14C: FOXO Tech Boosts Authorized Shares to 2.5B

FOXO Technologies Inc. has increased its authorized Class A Common Stock to 2.5 billion shares to meet existing financing obligations and enable future capital raising.

Summary

• The Board of Directors and the Majority Shareholder approved an amendment to increase the authorized Class A Common Stock from 500,000,000 shares to 2,500,000,000 shares.
• This increase is necessary to reserve shares for conversions of outstanding convertible debt, preferred stock, and warrants, which collectively require an estimated 2,487,646,350 shares.
• The company seeks greater flexibility for future financings, equity incentives for employees, strategic relationships, and potential acquisitions.
• The effective date for the increase is at the Board's discretion, but no later than March 31, 2026, and will occur at least 20 days after the mailing of this information statement.
• The action was approved by written consent of the Majority Shareholder (Rennova Health, Inc., controlled by the CEO), representing approximately 56.71% of the voting stock, making a stockholder meeting unnecessary.

Sentiment

Score: 6

Explanation: While the increase in authorized shares is a necessary step to meet existing obligations and enable future financing, the significant potential for dilution of existing stockholders and the possibility of using shares to deter takeovers introduce a degree of caution. It addresses a structural need but highlights potential future dilution.

Positives

• Provides the company with the necessary authorized shares to comply with existing financing agreements and satisfy conversion obligations.
• Offers greater flexibility for future capital raising, equity incentives, strategic partnerships, and potential business expansion through acquisitions.

Negatives

• Future issuance of additional shares for conversions, debt settlement, or capital raising will dilute existing stockholders.
• The increase in authorized shares could be used by the Board to oppose hostile takeover attempts or delay changes in control, potentially preventing stockholders from receiving a premium for their shares.

Risks

• Significant dilution of existing stockholders due to the future issuance of a large number of shares for conversions of preferred stock, convertible debt, and warrants, as well as for future capital raises.
• The potential for the Board to utilize the increased authorized shares as an anti-takeover defense, which could entrench current management and prevent transactions that might be beneficial to stockholders.

Future Outlook

The company anticipates using the additional authorized shares for various purposes, including conversion of Preferred Stock, settlement of debt, raising capital, providing equity incentives to employees, officers or directors, establishing strategic relationships with other companies, and expanding business or product lines through acquisitions. The Board may also use these additional shares to oppose hostile takeover attempts or to delay or prevent changes in control or management of the company.

Management Comments

• "The Board of Directors believes that the increase in our authorized Common Stock will allow us to comply with existing financing agreements and will also provide us greater flexibility with respect to the Company's capital structure for purposes of obtaining additional financing."

Industry Context

This action is a common corporate governance move for companies with complex capital structures involving convertible securities, aiming to ensure sufficient shares are available to meet conversion obligations and facilitate future growth or financing needs. It reflects a proactive approach to managing potential dilution from existing instruments and preparing for future capital requirements, a trend seen across various growth-oriented sectors.

Corporate Governance

Related Party Transactions

• Rennova Health, Inc., controlled by CEO Seamus Lagan, is the Majority Shareholder and holds 8,050 shares of Series A Preferred Stock.
• Rennova Health, Inc. has entered into Voting Agreements and Irrevocable Proxies with Sabby Volatility Warrant Master Fund, Ltd., Sabby Healthcare Master Fund, Ltd., and Chris Diamantis, granting RHI sole discretion over their voting shares, resulting in a combined voting percentage of approximately 56.71%.

Stakeholder Impact

• Shareholders: Potential for significant dilution of existing common stock holders due to future conversions and issuances. No dissenters' or appraisal rights are available.
• Management/Board: Increased flexibility in managing capital structure, pursuing financing, and potentially defending against hostile takeovers.
• Convertible Security Holders: Ensures sufficient shares are available for their conversion rights.

Next Steps

• The Board will determine the effective date for the Authorized Increase.
• The company will file an amendment to its Certificate of Incorporation with the Secretary of State of Delaware to effect the increase, no less than 20 days after the mailing of this information statement.
• The Authorized Increase may be abandoned by the Board at any time prior to filing the Certificate of Amendment.

Key Dates

Recommendation

The increase in authorized shares is a necessary, albeit dilutive, step to address existing conversion obligations and enable future financing. While it provides operational flexibility, the substantial potential for dilution from the 2.5 billion authorized shares, especially given the current outstanding shares, warrants a cautious 'hold' stance. Investors should monitor the actual issuance of these shares and the terms of future financings, as significant dilution could negatively impact per-share-value. The move is expected given the company's capital structure, but the execution and impact on shareholder value remain key considerations.

Keywords

FOXO Technologies, Authorized Shares, Stock Dilution, Capital Structure, SEC Filing, DEF 14C, Common Stock, Preferred Stock Conversion, Warrants, Corporate Governance, Rennova Health